Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR20013 vs palonosetron for prevention of chemotherapy-induced nausea and vomiting in moderately emetogenic regimens
CTR20243064Phase 3Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rolapitant + palonosetron in chemotherapy-induced nausea and vomiting (CINV) and Non-hematologic malignancy (2 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Complete response in delayed phase. Started Aug 2024; status: completed.
02
Drugs
rolapitant + palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20243064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243064.